Pharma industry has more in common with Martin Shkreli than it likes to admit
Quotes Paul Argenti in an article on why it is difficult for the American public to differentiate between Martin Shkreli and other pharma companies. “Most people don’t differentiate between Shkreli and other companies. It’s not enough to say that he’s worse when your own prices and profits are going up. That argument isn’t working. Most people lump them together.”